During his or her lifetime, every human being is infected with at least one of the nine human herpesviruses. In most cases, the immune system of healthy people keeps the infection under control and severe illness only rarely develops. Herpesviruses have adapted excellently to their host – they manipulate the immune system in many different ways and manage to remain in the host for life. If the immune system is weakened, herpesviruses can replicate and cause serious complications, including cancer.
To be able to successfully treat infections with this herpesvirus, we need to understand in detail how it controls our immune system.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a member of the human herpesvirus family. KSHV can cause three different forms of cancer: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease, affecting blood vessels, white blood cells, and lymph nodes, respectively. Kaposi’s sarcoma occurs frequently in AIDS patients whose immune systems are severely weakened by infection with human immunodeficiency virus 1 (HIV-1). So far, no vaccine against KSHV exists. The mechanisms used by this virus to manipulate its host and that lead to the development of cancer are also not fully understood. “To be able to successfully treat infections with this herpesvirus, we need to understand in detail how it controls our immune system”, says Prof Melanie Brinkmann, who leads the research group “Viral Immune Modulation” at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany and is a professor at the Hannover Medical School (MHH).
To gain insight into how KSHV escapes immune control, the Brinkmann research group has investigated a poorly understood protein of this virus, the protein ORF20. With mass spectrometric analysis, the researchers found that ORF20 forms a complex with a host protein of the innate immune defence system. “Normally, this host protein, known as OASL, is used to defend the host and has an antiviral function,” says Dr Kendra Bussey, a scientist in Brinkmann’s team and lead author of the study. “However, we have now shown for the first time that OASL has a proviral function during KSHV infection – the presence of OASL favours progression of the infection, rather than stopping it.” Using genetically modified viruses, the scientists were able to show that OASL only has a proviral effect if the viral protein ORF20 is present. “This shows that KSHV can skillfully manipulate the host for its own benefit, beating the host with its own weapon, so to speak”, says Bussey.
Melanie Brinkmann and her team have carried out this research within the framework of a collaborative research centre (CRC900) funded by the German Research Foundation (DFG). In the future, in collaboration with researchers from the HZI and the MHH, they hope to gain further understanding regarding the cellular immune system control levers manipulated by KSHV to circumvent defences of the immune system. “This will provide us with new insights into the interaction between the virus and its host, and hopefully enable us to understand how this virus contributes to the development of cancer by manipulating the immune response”, says Brinkmann.
Original publication:
Kendra A. Bussey, Ulrike Lau, Sophie Schumann, Antonio Gallo, Lisa Osbelt, Markus Stempel, Christine Arnold, Josef Wissing, Hans Henrik Gad, Rune Hartmann, Wolfram Brune, Lothar Jänsch, Adrian Whitehouse, Melanie M. Brinkmann: The interferon-stimulated gene product oligoadenylate synthetase-like protein enhances replication of Kaposi's sarcoma-associated herpesvirus (KSHV) and interacts with the KSHV ORF20 protein. PLOS Pathogens, 2018, DOI: 10.1371/journal.ppat.1006937
